

Test Type: CHRONIC

TEF evaluation (PCB 118)

Time Report Requested: 15:09:47

Route: GAVAGE

CAS Number: 31508-00-6

First Dose M/F: NA / 03/26/04

Species/Strain: RATS/SD

Lab: BAT

| SPRAGUE-DAWLEY RATS FEMALE | 0 UG/KG | 4600 UG/KG | 4600 UG/KG STOP |
|----------------------------------|---------|------------|-----------------|
| Disposition Summary | | | |
| Animals Initially in Study | 80 | 80 | 50 |
| Early Deaths | | | |
| Accidently Killed | | | 1 |
| Moribund Sacrifice | 27 | 16 | 18 |
| Natural Death | 4 | 11 | 6 |
| Survivors | | | |
| Moribund Sacrifice | | | 1 |
| Terminal Sacrifice | 21 | 25 | 24 |
| Animals Examined Microscopically | 52 | 52 | 50 |

ALIMENTARY SYSTEM

| | | | |
|---|--------|----------|----------|
| Esophagus | (51) | (52) | (50) |
| Intestine Large, Cecum | (52) | (48) | (49) |
| Intestine Large, Colon | (52) | (48) | (49) |
| Schwannoma Malignant, Metastatic, Uterus | 1 (2%) | | |
| Intestine Large, Rectum | (52) | (50) | (49) |
| Intestine Small, Duodenum | (52) | (48) | (49) |
| Carcinoma, Metastatic, Uterus | | | 1 (2%) |
| Intestine Small, Ileum | (52) | (47) | (49) |
| Carcinoma, Metastatic, Uterus | | | 2 (4%) |
| Intestine Small, Jejunum | (52) | (48) | (49) |
| Liver | (52) | (49) | (49) |
| Carcinoma, Metastatic, Uterus | | | 2 (4%) |
| Cholangiocarcinoma | | 6 (12%) | 12 (24%) |
| Cholangiocarcinoma, Multiple | | 30 (61%) | 17 (35%) |
| Cholangioma | 1 (2%) | | |
| Hepatocellular Adenoma | | 10 (20%) | |
| Hepatocellular Adenoma, Multiple | | 14 (29%) | 1 (2%) |
| Hepatocellular Carcinoma | | 1 (2%) | |
| Hepatocholangioma | | 4 (8%) | |
| Schwannoma Malignant, Metastatic, Uterus | 1 (2%) | | |
| Mesentery | (2) | (9) | (9) |
| Carcinoma, Metastatic, Uterus | | | 4 (44%) |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

TEF evaluation (PCB 118)

Time Report Requested: 15:09:47

Route: GAVAGE

CAS Number: 31508-00-6

First Dose M/F: NA / 03/26/04

Species/Strain: RATS/SD

Lab: BAT

| SPRAGUE-DAWLEY RATS FEMALE | 0 UG/KG | 4600 UG/KG | 4600 UG/KG STOP |
|--|----------|------------|-----------------|
| Oral Mucosa | (1) | (3) | (0) |
| Squamous Cell Carcinoma | | 2 (67%) | |
| Pancreas | (52) | (47) | (49) |
| Carcinoma, Metastatic, Uterus | | | 4 (8%) |
| Schwannoma Malignant, Metastatic, Uterus | 1 (2%) | | |
| Acinus, Adenoma | | 1 (2%) | |
| Acinus, Carcinoma | | 1 (2%) | |
| Stomach, Forestomach | (52) | (51) | (49) |
| Squamous Cell Carcinoma | | | 1 (2%) |
| Squamous Cell Papilloma | | | 1 (2%) |
| Stomach, Glandular | (52) | (51) | (49) |
| Carcinoma, Metastatic, Uterus | | | 1 (2%) |
| Tongue | (0) | (0) | (1) |
| Tooth | (10) | (7) | (7) |
| Odontoma | 1 (10%) | | |
| CARDIOVASCULAR SYSTEM | | | |
| Blood Vessel | (52) | (51) | (50) |
| Heart | (52) | (50) | (50) |
| ENDOCRINE SYSTEM | | | |
| Adrenal Cortex | (52) | (49) | (49) |
| Adenoma | 2 (4%) | 4 (8%) | 1 (2%) |
| Carcinoma | 1 (2%) | | |
| Carcinoma, Metastatic, Thyroid Gland | 1 (2%) | | |
| Carcinoma, Metastatic, Uterus | | | 2 (4%) |
| Granulosa Cell Tumor Malignant, Metastatic, Ovary | | | 1 (2%) |
| Adrenal Medulla | (52) | (49) | (49) |
| Pheochromocytoma Benign | 3 (6%) | | 2 (4%) |
| Parathyroid Gland | (47) | (47) | (49) |
| Adenoma | | 1 (2%) | |
| Pituitary Gland | (52) | (52) | (50) |
| Pars Distalis, Adenoma | 16 (31%) | 4 (8%) | 12 (24%) |
| Pars Distalis, Adenoma, Multiple | 1 (2%) | | |
| Pars Distalis, Carcinoma | 2 (4%) | | 1 (2%) |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

TEF evaluation (PCB 118)

Time Report Requested: 15:09:47

Route: GAVAGE

CAS Number: 31508-00-6

First Dose M/F: NA / 03/26/04

Species/Strain: RATS/SD

Lab: BAT

| SPRAGUE-DAWLEY RATS FEMALE | 0 UG/KG | 4600 UG/KG | 4600 UG/KG STOP |
|--------------------------------------|---------|------------|-----------------|
| Thyroid Gland | (51) | (49) | (50) |
| C-cell, Adenoma | 9 (18%) | 6 (12%) | 5 (10%) |
| C-cell, Carcinoma | 2 (4%) | | |
| Follicular Cell, Adenoma | 1 (2%) | | |
| Follicular Cell, Carcinoma | | | 1 (2%) |
| GENERAL BODY SYSTEM | | | |
| None | | | |
| GENITAL SYSTEM | | | |
| Clitoral Gland | (52) | (49) | (48) |
| Ovary | (52) | (48) | (49) |
| Carcinoma, Metastatic, Uterus | | | 3 (6%) |
| Granulosa Cell Tumor Malignant | | | 1 (2%) |
| Luteoma | 1 (2%) | | |
| Uterus | (52) | (49) | (49) |
| Carcinoma | 2 (4%) | 3 (6%) | 11 (22%) |
| Polyp Stromal | 3 (6%) | 5 (10%) | 3 (6%) |
| Schwannoma Malignant | 1 (2%) | 1 (2%) | 2 (4%) |
| Squamous Cell Carcinoma | | | 1 (2%) |
| Bilateral, Polyp Stromal | | 1 (2%) | 1 (2%) |
| Vagina | (7) | (0) | (0) |
| Polyp, Multiple | 1 (14%) | | |
| Squamous Cell Carcinoma | 1 (14%) | | |
| HEMATOPOIETIC SYSTEM | | | |
| Bone Marrow | (52) | (52) | (50) |
| Lymph Node | (0) | (2) | (1) |
| Renal, Carcinoma, Metastatic, Uterus | | | 1 (100%) |
| Lymph Node, Mandibular | (51) | (51) | (50) |
| Lymph Node, Mesenteric | (52) | (47) | (49) |
| Spleen | (52) | (47) | (49) |
| Carcinoma, Metastatic, Uterus | | | 3 (6%) |
| Thymus | (51) | (49) | (50) |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

TEF evaluation (PCB 118)

Time Report Requested: 15:09:47

Route: GAVAGE

CAS Number: 31508-00-6

First Dose M/F: NA / 03/26/04

Species/Strain: RATS/SD

Lab: BAT

| SPRAGUE-DAWLEY RATS FEMALE | 0 UG/KG | 4600 UG/KG | 4600 UG/KG STOP |
|--|----------|------------|-----------------|
| INTEGUMENTARY SYSTEM | | | |
| Mammary Gland | (52) | (50) | (50) |
| Carcinoma | 2 (4%) | 2 (4%) | 2 (4%) |
| Fibroadenoma | 16 (31%) | 8 (16%) | 12 (24%) |
| Fibroadenoma, Multiple | 9 (17%) | | 5 (10%) |
| Skin | (52) | (51) | (50) |
| Fibroma | 2 (4%) | | 1 (2%) |
| Hemangiosarcoma | 1 (2%) | | |
| Keratoacanthoma | 1 (2%) | | |
| Schwannoma Malignant | 1 (2%) | 1 (2%) | |
| Subcutaneous Tissue, Schwannoma Malignant, Metastatic, Uterus | 1 (2%) | | |
| MUSCULOSKELETAL SYSTEM | | | |
| Bone | (52) | (52) | (50) |
| Skeletal Muscle | (0) | (0) | (2) |
| Carcinoma, Metastatic, Uterus | | | 1 (50%) |
| Granulosa Cell Tumor Malignant, Metastatic, Ovary | | | 1 (50%) |
| NERVOUS SYSTEM | | | |
| Brain | (52) | (52) | (50) |
| Carcinoma, Metastatic, Pituitary Gland | 2 (4%) | | 1 (2%) |
| Spinal Cord | (0) | (1) | (0) |
| RESPIRATORY SYSTEM | | | |
| Lung | (51) | (50) | (50) |
| Carcinoma, Metastatic, Thyroid Gland | 1 (2%) | | 1 (2%) |
| Carcinoma, Metastatic, Uterus | | | 2 (4%) |
| Cystic Keratinizing Epithelioma | | 12 (24%) | |
| Cystic Keratinizing Epithelioma, Multiple | | 8 (16%) | |
| Nose | (52) | (52) | (50) |
| Trachea | (51) | (52) | (50) |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

TEF evaluation (PCB 118)

Time Report Requested: 15:09:47

Route: GAVAGE

CAS Number: 31508-00-6

First Dose M/F: NA / 03/26/04

Species/Strain: RATS/SD

Lab: BAT

| SPRAGUE-DAWLEY RATS FEMALE | 0 UG/KG | 4600 UG/KG | 4600 UG/KG STOP |
|---|---------|------------|-----------------|
| SPECIAL SENSES SYSTEM | | | |
| Eye | (52) | (52) | (50) |
| Harderian Gland | (52) | (52) | (50) |
| URINARY SYSTEM | | | |
| Kidney | (52) | (50) | (49) |
| Carcinoma, Metastatic, Uterus | | | 1 (2%) |
| Granulosa Cell Tumor Malignant, Metastatic, Ovary | | | 1 (2%) |
| Renal Tubule, Carcinoma | | | 1 (2%) |
| Ureter | (0) | (0) | (2) |
| Urinary Bladder | (52) | (50) | (49) |
| Carcinoma, Metastatic, Uterus | | | 1 (2%) |
| SYSTEMIC LESIONS | | | |
| Multiple Organs | *(52) | *(52) | *(50) |
| Histiocytic Sarcoma | 1 (2%) | | |
| Lymphoma Malignant | 2 (4%) | 3 (6%) | |

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

TEF evaluation (PCB 118)

Time Report Requested: 15:09:47

Route: GAVAGE

CAS Number: 31508-00-6

First Dose M/F: NA / 03/26/04

Species/Strain: RATS/SD

Lab: BAT

| SPRAGUE-DAWLEY RATS FEMALE | 0 UG/KG | 4600 UG/KG | 4600 UG/KG STOP |
|----------------------------|---------|------------|-----------------|
|----------------------------|---------|------------|-----------------|

Tumor Summary for Females

| | | | |
|--|----|-----|----|
| Total Animals with Primary Neoplasms (b) | 48 | 45 | 44 |
| Total Primary Neoplasms | 83 | 128 | 94 |
| Total Animals with Benign Neoplasms | 43 | 36 | 30 |
| Total Benign Neoplasms | 67 | 78 | 44 |
| Total Animals with Malignant Neoplasms | 15 | 39 | 37 |
| Total Malignant Neoplasms | 16 | 50 | 50 |
| Total Animals with Metastatic Neoplasms | 4 | | 9 |
| Total Metastatic Neoplasms | 8 | | 33 |
| Total Animals with Malignant Neoplasms Uncertain Primary Site | | | |
| Total Animals with Neoplasms Uncertain-Benign or Malignant | | | |
| Total Uncertain Neoplasms | | | |

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors